Tarsus Pharmaceuticals, Inc. TARS Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s business segments — R&D?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — R&D of $22.35M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — R&D changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — R&D increased by 55.1% year-over-year, from $14.41M to $22.35M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — R&D?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — R&D has grown at a 14.7% compound annual growth rate (CAGR), from $42.62M to $64.32M.
- What does business segments — R&D mean?
- Captures the expenditures incurred for the discovery, clinical development, and regulatory approval of new therapeutic candidates. For a biopharmaceutical company, this reflects the level of investment in the future pipeline and long-term innovation strategy.